全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Yosuke Miura , Takuma Yokoyama ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing of TRT combined with chemotherapy has not been fully evaluated.
作者:Yosuke Miura , Kyoichi Kaira ...
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2017, Vol.22 (5), pp.872-879Springer
摘要:Glucose-regulated protein (GRP) 78/immunoglobulin heavy chain binding protein (BiP) is a member of the endoplasmic reticulum chaperone family, and its role in various types of human malignancies has recently been investigated. However, the clinicopathological characteristics of G...
作者:Yosuke Miura , Makiko Yomota ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly patients. The addition of bevacizumab to docetaxel seems promising; however, the feasibility of this combination has not been investigated in such p...
作者:Yosuke Miura , Akihiko Gemma ...
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2015, Vol.20 (4), pp.659-667Springer
摘要:Abstract(#br) Purpose(#br)To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted.(#br) Methods(#br)Patients wi...
作者:Yosuke Miura , Kyoichi Kaira ...
来源:[J].Lung Cancer(IF 3.392), 2018, Vol.115, pp.42-48Elsevier
摘要:Abstract(#br)Objectives(#br)Amrubicin monotherapy is a treatment option for patients with relapsed small cell lung cancers (SCLCs). Topoisomerase-II (Topo-II) – a target of amrubicin – has been reported as a predictive or prognostic marker for chemosensitivity or outcomes in...
作者:Yosuke Miura , Kaori Seki ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.79 (3), pp.497-505Springer
摘要:Abstract(#br) Purpose(#br)In patients with epidermal growth factor receptor ( EGFR )-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutat...
作者:Yosuke Miura , Kaori Seki ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2015, Vol.76 (4), pp.761-769Springer
摘要:Abstract(#br) Purpose(#br)The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR mutation has not been elucidated. Therefore, the objective of this study was to inv...
作者:Yosuke Miura , Akihiro Yoshii ...
来源:[J].Lung Cancer(IF 3.392), 2013, Vol.82 (1), pp.103-108Elsevier
摘要:Abstract(#br)Background(#br)We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).(#br)Patients and methods(#br)Ch...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×